Stratos Wealth Partners LTD. Has $98,000 Holdings in Celldex Therapeutics, Inc. (CLDX)

Share on StockTwits

Stratos Wealth Partners LTD. trimmed its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 92.0% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 20,000 shares of the biopharmaceutical company’s stock after selling 230,000 shares during the period. Stratos Wealth Partners LTD.’s holdings in Celldex Therapeutics were worth $98,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Telemetry Investments L.L.C. grew its stake in Celldex Therapeutics by 87.2% during the fourth quarter. Telemetry Investments L.L.C. now owns 348,501 shares of the biopharmaceutical company’s stock worth $69,000 after buying an additional 162,301 shares in the last quarter. Virtu Financial LLC boosted its stake in shares of Celldex Therapeutics by 72.2% in the 1st quarter. Virtu Financial LLC now owns 25,826 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 10,825 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Celldex Therapeutics by 9.0% in the 4th quarter. Geode Capital Management LLC now owns 1,119,913 shares of the biopharmaceutical company’s stock valued at $221,000 after purchasing an additional 92,792 shares in the last quarter. Acadian Asset Management LLC boosted its stake in shares of Celldex Therapeutics by 26.5% in the 4th quarter. Acadian Asset Management LLC now owns 1,373,376 shares of the biopharmaceutical company’s stock valued at $272,000 after purchasing an additional 287,281 shares in the last quarter. Finally, Two Sigma Investments LP boosted its stake in shares of Celldex Therapeutics by 1.5% in the 4th quarter. Two Sigma Investments LP now owns 1,741,075 shares of the biopharmaceutical company’s stock valued at $345,000 after purchasing an additional 25,859 shares in the last quarter. Hedge funds and other institutional investors own 21.30% of the company’s stock.

CLDX opened at $3.18 on Monday. Celldex Therapeutics, Inc. has a 1-year low of $2.74 and a 1-year high of $11.63. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.41 and a current ratio of 7.41. The company has a market capitalization of $43.78 million, a PE ratio of -0.47 and a beta of 4.13.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.95) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.25. Celldex Therapeutics had a negative net margin of 729.59% and a negative return on equity of 45.09%. The company had revenue of $1.76 million for the quarter, compared to the consensus estimate of $1.46 million. On average, analysts expect that Celldex Therapeutics, Inc. will post -4.8 earnings per share for the current year.

CLDX has been the topic of a number of research analyst reports. Zacks Investment Research upgraded shares of Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 price target on the stock in a research note on Tuesday, February 19th. ValuEngine upgraded shares of Celldex Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, March 7th. Finally, HC Wainwright set a $19.00 price target on shares of Celldex Therapeutics and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Celldex Therapeutics currently has an average rating of “Buy” and an average target price of $12.38.

WARNING: This piece of content was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.tickerreport.com/banking-finance/4354066/stratos-wealth-partners-ltd-has-98000-holdings-in-celldex-therapeutics-inc-cldx.html.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.

Featured Story: What is the Gross Domestic Product (GDP)?

Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).

Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Comparing ENDRA Life Sciences  and The Competition
Comparing ENDRA Life Sciences and The Competition
Head-To-Head Comparison: CHESAPEAKE FINL/SH  versus Washington Federal
Head-To-Head Comparison: CHESAPEAKE FINL/SH versus Washington Federal
China Jo-Jo Drugstores  vs. 111  Head-To-Head Contrast
China Jo-Jo Drugstores vs. 111 Head-To-Head Contrast
Critical Analysis: Workhorse Group  & PACCAR
Critical Analysis: Workhorse Group & PACCAR
Reviewing Axos Financial  and BBX Capital
Reviewing Axos Financial and BBX Capital
Transatlantic Capital  and Digipath  Critical Survey
Transatlantic Capital and Digipath Critical Survey


© 2006-2019 Ticker Report